Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Fujifilm, FunPep Join Hands to Create Middle-Molecule Antiviral for HPV
May 16, 2017
- Otsuka to Build Its 6th Drug Factory in Japan, Launch Slated for 2020
May 16, 2017
- Otsuka, Hiroshima Univ. Spinout to Collaborate on CNS Cell Therapies
May 16, 2017
- Seikagaku, Ono to Link Up on Osteoarthritis Treatment
May 16, 2017
- Takeda to Split Part of Research Biz Into New Subsidiary
May 16, 2017
- Suzuken Embarking on Organizational Reforms to Eliminate “High-Cost Structure,” Improve SGA Cost Ratio
May 16, 2017
- Kyorin Poised to Weather Kipres Cliff with Consecutive Drug Launches: President
May 15, 2017
- Santen to Take Another Stab at US Market, Eyes Stand-Alone Sales Force
May 15, 2017
- Astellas Ditches ASP8273 as NSCLC Treatment
May 15, 2017
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
- No Plan for LLP Split-Off at This Point: Sumitomo Dainippon Chief
May 15, 2017
- Sumitomo Dainippon Scores Record Earnings on Latuda Boost
May 15, 2017
- Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
- Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
May 12, 2017
- AZ Union Petitions Court to Adjudicate Labor Dispute, Claiming Unfair Demotions and Pay Cuts
May 12, 2017
- Mitsubishi Tanabe to Transfer Production of Medway to Outside Party
May 12, 2017
- Chugai Grants JW Pharmaceutical Marketing Rights for Emicizumab in South Korea
May 12, 2017
- Astellas, Univ. of Tokyo to Expand Research Collaboration on Rice-Based Oral Vaccine
May 12, 2017
- Baxalta Files Patent Infringement Lawsuit against Chugai over Development of Hemophilia A Treatment Emicizumab in US
May 12, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…